In addition, spironolactone significantly attenuated the diabetes-induced increase in both urine MMP2 and MMP9 activities (Figure 4, C and F), confirming that MR antagonism reduced the activity of both MMPs in vivo. This evidence concerns the gene MMP9 and diabetes mellitus.